Advent Technologies (ADN) Q4 2023 earnings summary

Executive summary

• Focus shifted to high-temperature PEM fuel cell technology and MEA innovation, with a business model centered on technology transfer, licensing, and joint development agreements with OEMs and Tier 1s.

• Strategic partnerships established with Airbus, Hyundai, Siemens Energy, and the US Army, validating Ion Pair MEA technology and meeting all contractual milestones.

• Restructuring led to closure of unprofitable subsidiaries and a 70% reduction in targeted costs for 2024, aiming for a lean, technical team and minimal cash burn.

• Partnerships and technology advances have doubled power density and lifetime over previous fuel cells.

Financial highlights

• Q4 2023 revenue was $1.5 million, with total Q4 revenue and grant income at $2.3 million, down 3.6% year-over-year; full year 2023 total was $7.4 million, down 20.9% year-over-year.

• Net loss for Q4 was $25.7 million ($12.04/share); adjusted net loss was $22.1 million ($10.32/share), excluding a $3.71 million impairment charge.

• Operating expenses for 2023 were $44.6 million, down $1.1 million year-over-year; Q4 operating expenses were $10.7 million, down $1 million year-over-year.

• Unrestricted cash reserves stood at $3.6 million as of December 31, 2023, insufficient for the next 12 months of planned operations.

• Adjusted EBITDA for Q4 2023 was $(20.95) million, compared to $(53.22) million in Q4 2022.

Outlook and guidance

• No revenue guidance for 2024 due to uncertainty in contract timing and market conditions; management aims to operate near break-even, relying on OEM partnerships and R&D government funds.

• Focus for the next 18 months is on partnerships, MEA development, and licensing, not on revenue growth at any cost.

• Targeting EBITDA positive operation by 2025 and positioning for mass market scale-up post-2026.

• Revenue decline in 2023 is viewed as temporary, attributed to strategic reduction in direct sales and focus on core technology.